Department of Gynecology, Obstetrics and Oncology of the Jagiellonian University, Krakow, Poland.
Am J Reprod Immunol. 2010 May;63(5):387-95. doi: 10.1111/j.1600-0897.2009.00806.x. Epub 2010 Feb 8.
The relationship between endometriosis and cancer has been widely discussed in the literature but is still not well clarified. Perhaps significantly, soluble human leukocyte antigen-G (sHLA-G) has been identified in the microenvironment of both ovarian cancer and endometrioma. The aim of this study has been to evaluate the sHLA-G levels in the blood sera of women with deep endometriosis and ovarian endometrioma over the course of the menstrual cycle and to compare to the levels of sHLA-G in the blood sera of women with ovarian cancer.
In our study, we examined the blood sera obtained from 123 patients operated on because of ovarian cancer (65 cases), ovarian endometrioma (30 cases), and deep endometriosis (28 cases). We decided to compare the levels of sHLA-G in patients with endometriosis to those found in patients with ovarian cancer with respect to the menstrual cycle phases. The sHLA-G concentration level was measured by enzyme-linked immunosorbent assay kit.
The level of sHLA-G concentration in the blood serum of patients with deep endometriosis fluctuates over the course of the menstrual cycle, and during the proliferative and secretory phases, it remains at a high level comparable to that found in patients with ovarian cancer. By contrast, the level of sHLA-G concentration in the blood serum of patients with ovarian endometrioma fluctuates minimally over the course of the different menstrual cycle phases and, as in patients with ovarian cancer, it remains at high level during the proliferative phase.
sHLA-G blood serum concentration levels would seem to provide important information regarding the degree of immune system regulation disturbance in both ectopic endometrial cells and the cancer cell suppressive microenvironment.
子宫内膜异位症和癌症之间的关系在文献中已经广泛讨论，但仍未得到很好的阐明。也许值得注意的是，可溶性人类白细胞抗原-G（sHLA-G）已在卵巢癌和子宫内膜异位瘤的微环境中被发现。本研究旨在评估在月经周期过程中患有深部子宫内膜异位症和卵巢子宫内膜异位瘤的妇女的血清中 sHLA-G 水平，并将其与患有卵巢癌的妇女的血清中 sHLA-G 水平进行比较。
在我们的研究中，我们检查了因卵巢癌（65 例）、卵巢子宫内膜异位瘤（30 例）和深部子宫内膜异位症（28 例）而接受手术的 123 名患者的血清。我们决定根据月经周期阶段比较子宫内膜异位症患者和卵巢癌患者的 sHLA-G 水平。sHLA-G 浓度水平通过酶联免疫吸附测定试剂盒进行测量。
深部子宫内膜异位症患者血清中 sHLA-G 浓度在月经周期中波动，在增生期和分泌期保持与卵巢癌患者相当的高水平。相比之下，卵巢子宫内膜异位瘤患者血清中 sHLA-G 浓度在不同月经周期阶段波动很小，并且与卵巢癌患者一样，在增生期仍保持高水平。
sHLA-G 血清浓度似乎为异位子宫内膜细胞和癌细胞抑制性微环境中免疫系统调节紊乱的程度提供了重要信息。
